What is the difference between Nurtec ODT and Ubrelvy?

Same class. Both Nurtec ODT and Ubrelvy are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.

Are Nurtec ODT and Ubrelvy the same drug?

No. Nurtec ODT is the brand name for Rimegepant and Ubrelvy is the brand name for Ubrogepant. They are different active ingredients.

Is Nurtec ODT a tablet or an injection?

Nurtec ODT is given by the oral route; Ubrelvy by the oral route.

Who makes Nurtec ODT and Ubrelvy?

Nurtec ODT is marketed by Pfizer; Ubrelvy by AbbVie. (FDA application holder, per Drugs@FDA.)

Nurtec ODT vs Ubrelvy: How Rimegepant and Ubrogepant Compare

Reviewed by the Priya Life Science Editorial Team, led by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from official FDA data · Last verified 6 Aug 2026 · Editorial standards

At a glance

Nurtec ODTRimegepant

UbrelvyUbrogepant

Brand names

Nurtec ODT / Vydura

Ubrelvy

Drug class

CGRP receptor antagonist

Route

Oral

Marketed by

Pfizer

AbbVie

First FDA approval

27 Feb 2020

23 Dec 2019

US shortage

Not listed

Key differences

Same class. Both Nurtec ODT and Ubrelvy are CGRP inhibitors, so they work through the same broad mechanism. Differences between them tend to be about dosing, route, how selective they are, and side effects rather than what they target.
How they are taken. Both are given by the oral route.
Time on the market. Nurtec ODT was first approved by the FDA in 2020, Ubrelvy in 2019.
Who markets them. Nurtec ODT is marketed by Pfizer; Ubrelvy by AbbVie.
Same drug, more than one brand. Rimegepant is sold as Nurtec ODT / Vydura — the same active ingredient marketed under different brand names, typically for different approved uses or doses.

What each one treats

Nurtec ODTRimegepant

NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: acute treatment of migraine with or without aura in adults ( 1.1 ) preventive treatment of episodic migraine in adults ( 1.2 ) 1.1 Acute Treatment of Migraine NURTEC ODT is indicated for the acute treatment of migraine with or without aura in adults . 1.2 Preventive Treatment of Episodic Migraine NURTEC ODT is indicated for the preventive treatment of episodic migraine in adults.

UbrelvyUbrogepant

UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. UBRELVY is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. ( 1 ) Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. ( 1 )

How each one works

Nurtec ODTCGRP receptor antagonist

12.1 Mechanism of Action Rimegepant is a calcitonin gene-related peptide receptor antagonist.

UbrelvyCGRP receptor antagonist

12.1 Mechanism of Action Ubrogepant is a calcitonin gene-related peptide receptor antagonist.

Related comparisons

Aimovig VS Nurtec ODT Aimovig VS Ubrelvy Emgality VS Nurtec ODT Emgality VS Ubrelvy Ajovy VS Nurtec ODT Ajovy VS Ubrelvy

Nurtec ODT profile Ubrelvy profile CGRP Inhibitors All comparisons

This is not a recommendation of one drug over the other.

Which medicine is right for a given person depends on their diagnosis, other conditions, other medicines, kidney and liver function, pregnancy, and cost or reimbursement — none of which this page knows. Two drugs in the same class are not automatically interchangeable. Never start, stop or switch a prescription medicine on the basis of a web page; that decision belongs to you and your clinician or pharmacist.

How this page is built

The facts on this page are pulled directly from official U.S. FDA datasets — they are not written from memory. Each field below names the dataset it came from, so you can check it yourself.

FDA Drug Label (openFDA) ↗ Indications, mechanism of action and pharmacologic class
Drugs@FDA ↗ First FDA approval date and the company holding the application
FDA Drug Shortage Database ↗ Current US supply / shortage status

Plain-English summaries and drug-class explainers are written and reviewed by the Priya Life Science editorial team, led by Sreepriya Prasannan (MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany). Data is retrieved automatically from the sources above and cross-checked with AI-assisted verification (Anthropic's Claude) — brand and generic names are matched against the exact FDA product record so that a combination product or a different formulation cannot be mistaken for the drug on this page. An editor reviews the result before publication. We describe this in full in our editorial standards and corrections policy. The FDA data on this page was last retrieved on 6 Aug 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Nurtec ODT vs Ubrelvy